bioRxivCancer BiologyPreprint
Mcam stabilizes luminal progenitor breast cancer phenotypes via Ck2 control and Src/Akt/Stat3 attenuation
O. Balcioglu, B. L. Gates, D. W. Freeman, B. M. Hagos, E. M. Mehrabad, D. Ayala-Talavera, B. T. Spike
Abstract
Breast cancers are categorized into subtypes with distinctive therapeutic vulnerabilities and prognoses based on their expression of clinically targetable receptors and gene expression patterns mimicking different cell types of the normal gland. Here, we tested the role of Mcam in breast cancer cell state control and tumorigenicity in a luminal progenitor-like murine tumor cell line (Py230) that exhibits lineage and tumor subtype plasticity. Mcam knockdown Py230 cells show augmented Stat3 and Pi3K/Akt activation associated with a lineage state switch away from a hormone-sensing/luminal progenitor state toward alveolar and basal cell related phenotypes that were refractory to growth inhibition by the anti-estrogen therapeutic, tamoxifen. Inhibition of Stat3, or the upstream activator Ck2, reversed these cell state changes. Mcam binds Ck2 and acts as a regulator of Ck2 substrate utilization across multiple mammary tumor cell lines. In Py230 cells this activity manifests as increased mesenchymal morphology, migration, and Src/Fak/Mapk/Paxillin adhesion complex signaling in vitro, in contrast to Mcams reported roles in promoting mesenchymal phenotypes. In vivo, Mcam knockdown reduced tumor growth and take rate and inhibited cell state transition to Sox10+/neural crest like cells previously been associated with tumor aggressiveness. This contrasts with human luminal breast cancers where MCAM copy number loss is highly coupled to Cyclin D amplification, increased proliferation, and the more aggressive Luminal B subtype. Together these data indicate a critical role for Mcam and its regulation of Ck2 in control of breast cancer cell state plasticity with implications for progression, evasion of targeted therapies and combination therapy design. HIGHLIGHTSO_LIMcam is expressed by diverse breast cancer subtypes. C_LIO_LIMcam regulates breast cancer cell state plasticity. C_LIO_LIMcam maintains the mammary luminal progenitor state. C_LIO_LIMcam attenuates Stat activity. C_LIO_LIMcam dictates Ck2 substrate utilization. C_LI
- organism: mouse
- assay: bulk RNA-seq
- research focus: cell type annotation
- research focus: cell signaling & trafficking
- research focus: cancer & tumor microenvironment
- research focus: development & morphogenesis
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- LMO2 regulates epithelial-mesenchymal plasticity of mammary epithelial cells
Veronica Haro Acosta, Andrew Olander, … Shaheen S. Sikandar·Journal of Mammary Gland Biology and NeoplasiaPeer-reviewed·Feb 9, 2026
- Loss of tumor suppressor p53 upregulates stem cell factor SOX9 via Notch signaling
Rahul Sanawar, Wenjun Guo·bioRxiv·May 27, 2025
- Pro- and anti-tumour activities of CD146/MCAM in breast cancer result from its heterogeneous expression and association with epithelial to mesenchymal transition
A. J. Mannion, A. F. Odell, … G. P. Cook·Frontiers in Cell and Developmental BiologyPeer-reviewed·Apr 17, 2023
- Transient CB2 receptor activation triggers irreversible luminal differentiation via chromatin remodeling in breast cancer
Nuria G. Martínez-Illescas, Gemma Pérez-García, … María Salazar‐Roa·bioRxiv·Jul 29, 2025
- TRIB1 modulates transcriptional programming in breast cancer cells to regulate cell proliferation
H. D. McMillan, E. K. Papachristou, … A. Dunbier·bioRxiv·Jul 6, 2023
- MAGI1 inhibits the AMOTL2/p38 stress pathway and prevents luminal breast tumorigenesis
D. Kantar, E. Bousquet Mur, … A. Djiane·bioRxiv·Jun 13, 2020